Using inhalable powders of viruses to treat tuberculosis
Inhalable dry powders of mycobacteriophages for tuberculosis therapy
This study is looking at a new way to treat tuberculosis (TB) using inhalable powders made from special viruses that can target and kill the TB bacteria directly in the lungs, aiming to make treatment easier and more effective than traditional antibiotics.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Via Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Austin, United States) |
| Project ID | NIH-11006022 on NIH RePORTER |
What this research studies
This research investigates the use of inhalable dry powders containing mycobacteriophages, which are viruses that specifically target and kill the bacteria causing tuberculosis (TB). The approach aims to deliver these phages directly to the lungs, where they can effectively eliminate Mycobacterium tuberculosis while minimizing damage to beneficial bacteria. By utilizing a novel thin-film freeze-drying technology, the researchers hope to create a stable and effective treatment that reduces the frequency and duration of therapy compared to traditional antibiotics, which often lead to resistance and non-compliance among patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with tuberculosis, particularly those with drug-resistant strains.
Not a fit: Patients who do not have tuberculosis or those with other unrelated respiratory conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and patient-friendly treatment option for tuberculosis, potentially reducing the burden of antibiotic resistance.
How similar studies have performed: Previous research has shown promise in using phage therapy for bacterial infections, indicating potential success for this novel approach in treating tuberculosis.
Where this research is happening
Austin, United States
- Via Therapeutics, LLC — Austin, United States (Active)
Researchers
- Principal investigator: Warnken, Zachary N — Via Therapeutics, LLC
- Study coordinator: Warnken, Zachary N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.